Skip to content

Standardized clinical research on Uyghur Sand Therapy for the dominant disease of "Abnormal Belghem" (chronic pelvic inflammation)

Standardized clinical research on Uyghur Sand Therapy for the dominant disease of "Abnormal Belghem" (chronic pelvic inflammation)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001854
Enrollment
Unknown
Registered
2025-09-26
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pelvic inflammation

Interventions

experimental group:Basic treatment in Uyghur medicine + sand therapy
control group:Basic treatment in Uyghur medicine

Sponsors

Xinjiang Uyghur Autonomous Region Uyghur Medical Hospital (Xinjiang Uyghur Autonomous Region Second People's Hospital)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for chronic pelvic inflammatory disease; (2) The course of the disease is more than one month; (3) Those aged between 18 and 45 with a history of sexual life; (4) It conforms to the abnormal Belghem type syndrome of Uyghur medicine; (5) Voluntarily participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those with a history of gynecological malignant lesions or precancerous lesions, pelvic abscess, total hysterectomy and other diseases; (2) Patients with severe diseases of the heart, brain, liver, kidneys, urinary system, digestive system, reproductive system, etc. (3) Those with concurrent neurological or mental disorders or poor compliance; (4) Those who are known to be allergic to the test drug (or its components); (5) Women who are pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Inflammation-related indicators: white blood cell count (WBC), neutrophil percentage, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), inflammatory cytokines (IL-6, TNF-a);Vaginal secretion test: microscopic examination of the number of white blood cells per high power field (WBC/HP), and cleanliness grading (grade I-IV);Pathogen clearance status, such as: bacterial culture (Neisseria gonorrhoeae, Chlamydia), PCR detection (Mycoplasma, anaerobic bacteria);Imaging improvement indicators for negative conversion rate (gynecological ultrasound), such as pelvic fluid depth/volume, pelvic abscess, and changes in tubal-ovarian structure;

Secondary

MeasureTime frame
12-Item Short-Form Health Survey, SF-12;McCormack rating;Improvement rate of HSG showing patent/partially patent/obstructed fallopian tubes;Uyghur medicine special syndrome scoring: scoring of symptoms related to "abnormal phlegm constitution";

Countries

China

Contacts

Public ContactAman GUL

Xinjiang Uyghur Autonomous Region Uyghur Medical Hospital (Xinjiang Uyghur Autonomous Region Second People's Hospital)

aytegin@outlook.com18690893065

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026